在小鼠模型中,APOE4可加剧由血液衍生的Aβ诱导的阿尔茨海默氏症类病态和认知缺陷
Zhong-Yuan Yu1, Xiao-Yu Liu1, Qiong-Yan Li1
1Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
Aging cell
|September 4, 2025
概括
Apolipoprotein E4 (APOE4) 促进血液衍生的粉样β进入大脑,恶化阿尔茨海默氏症
科学领域:
- 神经科学
- 遗传学
- 病理学
背景情况:
- Apolipoprotein E4 (APOE4) 是阿尔茨海默病 (AD) 的一个主要遗传风险因素.
- 连接APOE4和零星AD的机制尚未完全理解.
- 之前的研究强调血液衍生的β-粉样蛋白 (Aβ) 是阿尔茨海默氏症病理的贡献者.
研究的目的:
- 研究APOE4在血液中获得的Aβ进入大脑中的作用.
- 确定APOE4对由血液衍生的Aβ诱导的AD类病理的影响.
- 阐明APOE4如何增加偶发性阿尔茨海默病的风险.
主要方法:
- 使用了一种小鼠模型,从APP/PS1•APOE4小鼠移植到接受APOE4的小鼠中.
- 评估了血脑屏障的完整性.
- 大脑中的Aβ水平量化.
- 评估了的高化,神经炎症,神经元退化和认知功能.
主要成果:
- APOE4显著促进了血源Aβ进入大脑.
- 接受APOE4的小鼠表现出血脑屏障完整性受损以及脑Aβ水平升高.
- 在接受APOE4的患者中观察到恶化的陶过,神经炎症,神经元损失和行为缺陷.
结论:
- 通过血脑屏障增强了外围Aβ的转移.
- 由血液衍生的Aβ引发的AD类病态会被APOE4加剧.
- 这项研究提供了APOE4对偶发性AD病变的潜在机制.
更多相关视频
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.3K
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
27.1K
相关概念视频
01:26Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260